Your browser doesn't support javascript.
loading
Cerebral blood flow predicts differential neurotransmitter activity.
Dukart, Juergen; Holiga, Stefan; Chatham, Christopher; Hawkins, Peter; Forsyth, Anna; McMillan, Rebecca; Myers, Jim; Lingford-Hughes, Anne R; Nutt, David J; Merlo-Pich, Emilio; Risterucci, Celine; Boak, Lauren; Umbricht, Daniel; Schobel, Scott; Liu, Thomas; Mehta, Mitul A; Zelaya, Fernando O; Williams, Steve C; Brown, Gregory; Paulus, Martin; Honey, Garry D; Muthukumaraswamy, Suresh; Hipp, Joerg; Bertolino, Alessandro; Sambataro, Fabio.
Afiliación
  • Dukart J; F. Hoffmann-La Roche, pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland. juergen.dukart@gmail.com.
  • Holiga S; F. Hoffmann-La Roche, pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland.
  • Chatham C; F. Hoffmann-La Roche, pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland.
  • Hawkins P; Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.
  • Forsyth A; School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
  • McMillan R; School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
  • Myers J; Neuropsychopharmacology Unit, Imperial College London, London, United Kingdom.
  • Lingford-Hughes AR; Neuropsychopharmacology Unit, Imperial College London, London, United Kingdom.
  • Nutt DJ; Veterans Affairs San Diego Healthcare System, San Diego, USA.
  • Merlo-Pich E; F. Hoffmann-La Roche, pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland.
  • Risterucci C; F. Hoffmann-La Roche, pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland.
  • Boak L; F. Hoffmann-La Roche, pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland.
  • Umbricht D; F. Hoffmann-La Roche, pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland.
  • Schobel S; F. Hoffmann-La Roche, pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland.
  • Liu T; Center for Functional MRI, University of California San Diego, 9500 Gilman Drive MC 0677, La Jolla, CA 92093, United States.
  • Mehta MA; Departments of Radiology, Psychiatry and Bioengineering, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, United States.
  • Zelaya FO; Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.
  • Williams SC; Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.
  • Brown G; Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.
  • Paulus M; University of California, San Diego, La Jolla, USA.
  • Honey GD; Veterans Affairs San Diego Healthcare System, San Diego, USA.
  • Muthukumaraswamy S; University of California, San Diego, La Jolla, USA.
  • Hipp J; Veterans Affairs San Diego Healthcare System, San Diego, USA.
  • Bertolino A; F. Hoffmann-La Roche, pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland.
  • Sambataro F; School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
Sci Rep ; 8(1): 4074, 2018 03 06.
Article en En | MEDLINE | ID: mdl-29511260
Application of metabolic magnetic resonance imaging measures such as cerebral blood flow in translational medicine is limited by the unknown link of observed alterations to specific neurophysiological processes. In particular, the sensitivity of cerebral blood flow to activity changes in specific neurotransmitter systems remains unclear. We address this question by probing cerebral blood flow in healthy volunteers using seven established drugs with known dopaminergic, serotonergic, glutamatergic and GABAergic mechanisms of action. We use a novel framework aimed at disentangling the observed effects to contribution from underlying neurotransmitter systems. We find for all evaluated compounds a reliable spatial link of respective cerebral blood flow changes with underlying neurotransmitter receptor densities corresponding to their primary mechanisms of action. The strength of these associations with receptor density is mediated by respective drug affinities. These findings suggest that cerebral blood flow is a sensitive brain-wide in-vivo assay of metabolic demands across a variety of neurotransmitter systems in humans.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Imagen por Resonancia Magnética / Sistema Nervioso Central / Circulación Cerebrovascular / Neurotransmisores / Monitorización Neurofisiológica Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Sci Rep Año: 2018 Tipo del documento: Article País de afiliación: Suiza

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Imagen por Resonancia Magnética / Sistema Nervioso Central / Circulación Cerebrovascular / Neurotransmisores / Monitorización Neurofisiológica Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Sci Rep Año: 2018 Tipo del documento: Article País de afiliación: Suiza